Background: C is used at our center for empirical treatment of fever. Method: We reviewed the clinical records of the 156 SCT patients who received empirical C between 01/2004 and 04/2007 and developed BT IA (occurring > 6 days (d) after C initiation). Results: There were 9 BT IA (6%). The table shows patient and IA characteristics, and susceptibility testing of the isolates. Abbreviations: CR, complete response; Stab, stabilization; Fail, failure; AB, Amphotericin B; A, Anidulafungin; M, Micafungin; V, Voriconazole; NA, not available; * day post-transplant; **MIC, minimal inhibitory concentration (AB & V) & MEC, minimal effective concentration (echinocandins). Conclusion: It is unknown if the high incidence of BT IA in patients receiving empirical C (with high MECs to C for 2/4 isolates) represents a clinically meaningful limitation of C or if it reflects the poor immune status of the SCT population.
Full conference title:
47th Interscience Conference on Antimicrobial agents and Chemotherapy
- ICAAC 47th